Related Experiment Video

Updated: Jun 25, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Treatment for chronic hepatitis C in children: a review

Emilio Palumbo1

  • 1Department of Pediatric, Hospital of Sondrio, Sondrio, Italy. emipalu2003@yahoo.it

American Journal of Therapeutics
|March 6, 2009
PubMed

Insights

Hepatitis C virus (HCV) treatment in children shows improved outcomes with interferon (IFN) and ribavirin. Combination therapies, particularly with pegylated interferon, offer promising results and good tolerability in pediatric patients.

Area of Science:

  • Pediatric Gastroenterology and Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C virus (HCV) infection is a significant global health concern.
  • Effective treatment strategies for pediatric HCV are crucial for long-term health outcomes.
  • Limited data exists on the efficacy and safety of various HCV treatments in children.

Purpose of the Study:

  • To review current treatment modalities for chronic hepatitis C virus (HCV) in pediatric populations.
  • To evaluate the efficacy of interferon-based therapies in children.
  • To assess the safety and tolerability of different treatment regimens.

Main Methods:

  • Systematic review of published literature on HCV treatment in children.
  • Analysis of sustained virological response (SVR) rates for different therapeutic approaches.
  • Examination of treatment outcomes based on HCV genotype and combination therapies.

Main Results:

  • Interferon (IFN) monotherapy in children yields SVR rates of 33%-45%, superior to adult rates.
  • IFN monotherapy shows lower SVR for genotype 1 (26%) versus other genotypes (70%).
  • IFN-alpha2b combined with ribavirin demonstrates higher SVR in children (84% for genotype 2/3 vs. 36% for genotype 1).
  • Preliminary data suggests pegylated IFN-alpha2b with ribavirin is well-tolerated and effective in pediatric patients.

Conclusions:

  • Interferon-based therapies, especially combination treatments, are effective for chronic HCV in children.
  • HCV treatment outcomes in children may be influenced by disease stage, dosage, and comorbidities.
  • Further research into newer combination therapies like PEG-IFN-alpha2b with ribavirin is warranted for pediatric HCV management.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...